{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Glucan 1,3-beta-glucosidase : Questions médicales les plus fréquentes",
"headline": "Glucan 1,3-beta-glucosidase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Glucan 1,3-beta-glucosidase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-18",
"dateModified": "2025-02-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Glucan 1,3-beta-glucosidase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cellulases",
"url": "https://questionsmedicales.fr/mesh/D044602",
"about": {
"@type": "MedicalCondition",
"name": "Cellulases",
"code": {
"@type": "MedicalCode",
"code": "D044602",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.277.450.420.200"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Glucan 1,3-beta-glucosidase",
"alternateName": "Glucan 1,3-beta-Glucosidase",
"code": {
"@type": "MedicalCode",
"code": "D043326",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Johannes Wagener",
"url": "https://questionsmedicales.fr/author/Johannes%20Wagener",
"affiliation": {
"@type": "Organization",
"name": "Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Ludwig-Maximilians-Universität München, Munich, Germany."
}
},
{
"@type": "Person",
"name": "Shigekazu Yano",
"url": "https://questionsmedicales.fr/author/Shigekazu%20Yano",
"affiliation": {
"@type": "Organization",
"name": "Graduate School of Sciences and Engineering, Yamagata University."
}
},
{
"@type": "Person",
"name": "Malgorzata Mikulska",
"url": "https://questionsmedicales.fr/author/Malgorzata%20Mikulska",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Malcolm Finkelman",
"url": "https://questionsmedicales.fr/author/Malcolm%20Finkelman",
"affiliation": {
"@type": "Organization",
"name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA."
}
},
{
"@type": "Person",
"name": "Yonglong Zhang",
"url": "https://questionsmedicales.fr/author/Yonglong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The online mindset intervention 'The Growth Factory' for adolescents with intellectual disabilities: moderators and mediators.",
"datePublished": "2022-09-01",
"url": "https://questionsmedicales.fr/article/36047578",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jir.12970"
}
},
{
"@type": "ScholarlyArticle",
"name": "The adaptive ability performance test (ADAPT): A factor analytic study in clients with intellectual disabilities.",
"datePublished": "2022-10-26",
"url": "https://questionsmedicales.fr/article/36288909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jar.13044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Eye-tracking training improves the learning and memory of children with learning difficulty.",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/35977994",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-18286-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Aggressive behaviour of psychiatric patients with mild and borderline intellectual disabilities in general mental health care.",
"datePublished": "2022-10-03",
"url": "https://questionsmedicales.fr/article/36190995",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0272502"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prevalence and trends of developmental disabilities among US children and adolescents aged 3 to 17 years, 2018-2021.",
"datePublished": "2023-10-12",
"url": "https://questionsmedicales.fr/article/37828147",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-44472-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrolases",
"item": "https://questionsmedicales.fr/mesh/D006867"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosidases",
"item": "https://questionsmedicales.fr/mesh/D006026"
},
{
"@type": "ListItem",
"position": 6,
"name": "Glucosidases",
"item": "https://questionsmedicales.fr/mesh/D005959"
},
{
"@type": "ListItem",
"position": 7,
"name": "Cellulases",
"item": "https://questionsmedicales.fr/mesh/D044602"
},
{
"@type": "ListItem",
"position": 8,
"name": "Glucan 1,3-beta-glucosidase",
"item": "https://questionsmedicales.fr/mesh/D043326"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Glucan 1,3-beta-glucosidase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Glucan 1,3-beta-glucosidase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Glucan 1,3-beta-glucosidase",
"description": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?\nQuels tests sont utilisés pour mesurer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des marqueurs biologiques associés à cette enzyme ?\nComment les tests génétiques aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Glucan 1,3-beta-glucosidase",
"description": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?\nLa déficience peut-elle causer des problèmes immunitaires ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Glucan 1,3-beta-glucosidase",
"description": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?\nY a-t-il des mesures préventives pour les symptômes ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation des patients est-elle importante ?\nLes conseils diététiques peuvent-ils prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Glucan 1,3-beta-glucosidase",
"description": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des thérapies alternatives recommandées ?\nLa diététique joue-t-elle un rôle dans le traitement ?\nDes traitements expérimentaux sont-ils disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Glucan 1,3-beta-glucosidase",
"description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle entraîner des infections fréquentes ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être évitées ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Glucan 1,3-beta-glucosidase",
"description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque de déficience ?\nLes facteurs environnementaux influencent-ils le risque ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes facteurs socio-économiques influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Learning+Disabilities&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests enzymatiques et des analyses génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour mesurer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques spécifiques mesurent l'activité de la glucan 1,3-beta-glucosidase dans les échantillons."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des douleurs abdominales ou des troubles digestifs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques associés à cette enzyme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de glucanes dans le sang peuvent servir de marqueurs biologiques."
}
},
{
"@type": "Question",
"name": "Comment les tests génétiques aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils identifient des mutations spécifiques dans le gène codant pour l'enzyme, confirmant le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, douleurs abdominales, et troubles de la digestion."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle causer des problèmes immunitaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une déficience peut affecter le système immunitaire, augmentant la susceptibilité aux infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir, bien que moins fréquents, comme des maux de tête."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la déficience."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être gérés, mais la déficience elle-même est généralement permanente."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déficience est généralement génétique, donc la prévention n'est pas possible."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les symptômes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications alimentaires et un suivi médical régulier peuvent aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les porteurs et informer sur les risques."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la maladie et ses symptômes est cruciale pour une gestion efficace."
}
},
{
"@type": "Question",
"name": "Les conseils diététiques peuvent-ils prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conseils diététiques appropriés peuvent aider à prévenir des complications digestives."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments enzymatiques et des modifications alimentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à gérer les symptômes ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent être prescrits pour soulager les symptômes digestifs et la douleur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives recommandées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives, comme la phytothérapie, peuvent être envisagées, mais avec prudence."
}
},
{
"@type": "Question",
"name": "La diététique joue-t-elle un rôle dans le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation adaptée peut aider à réduire les symptômes et améliorer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Des traitements expérimentaux sont-ils disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur des traitements expérimentaux, mais ils ne sont pas encore largement disponibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec cette déficience ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications digestives, immunitaires et neurologiques peuvent se développer."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle entraîner des infections fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une déficience en glucan 1,3-beta-glucosidase peut augmenter le risque d'infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications à long terme peuvent inclure des troubles digestifs chroniques et des infections récurrentes."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par une gestion proactive des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette déficience ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque de déficience ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge peut influencer l'apparition des symptômes, mais la déficience est généralement génétique."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'y a pas de preuves solides que les facteurs environnementaux influencent ce risque."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents médicaux de troubles digestifs peuvent augmenter la suspicion de déficience."
}
},
{
"@type": "Question",
"name": "Les facteurs socio-économiques influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs socio-économiques peuvent affecter l'accès aux soins, mais pas directement le risque génétique."
}
}
]
}
]
}
The online mindset intervention The Growth Factory (TGF) has shown promising effects-increasing growth mindsets and perseverance and decreasing mental health problems among youth with intellectual dis...
The sample consisted of 119 participants with mild to borderline ID (M...
Findings indicated that the effectiveness of TGF was not affected by participants' baseline mindsets, age and ID level. TGF was more effective in reducing internalising problems in girls and increasin...
TGF offers a universal, 'add-on' mindset intervention complementing usual care programmes. It improves mindsets, perseverance and mental health in youth with ID. Both practical and theoretical implica...
The adaptive ability performance test (ADAPT) was developed to assess adaptive skills in individuals with intellectual disabilities and borderline intellectual functioning, with or without mental diso...
One thousand and sixty six ADAPTs from clients with (suspected) intellectual disabilities or borderline intellectual functioning and 129 ADAPTs from participants from the general population were colle...
An exploratory factor analysis (EFA) was performed and resulted in good fit indices. Subsequent confirmatory factor analysis (CFA) and multigroup CFA showed acceptable to good fit indices. This result...
Factor analytic results suggest that the ADAPT is a valid instrument that measures adaptive skills in individuals with intellectual disabilities or borderline intellectual functioning....
Children who experience difficulty in learning at mainstream schools usually are provided with remediation classes after school to facilitate their learning. The present study aims to evaluate an inno...
Little is known about the associations between mild intellectual disability (MID), borderline intellectual functioning (BIF) and aggressive behaviour in general mental health care. The study aims to e...
1174 out of 1565 consecutive in-and outpatients were screened for MID/BIF with the Screener for Intelligence and Learning Disabilities (SCIL) in general mental health care in The Netherlands. During t...
Forty-one percent of participating patients were screened positive for MID/BIF. Patients with assumed MID/BIF showed significantly more aggression at the patient and sample level (odds ratio (OR) of 2...
We found an increased risk for aggression and physical aggression in patients with assumed MID/BIF. We recommend screening for intellectual functioning at the start of treatment and using measures to ...
Developmental disabilities prevalence seem to be high in countries around the world. It's worth understanding the most recent prevalence and trends of developmental disabilities. The objective of this...
Multiple measures of mental health problems and mental wellbeing for adults with intellectual disabilities are available, but investigations into their reliability and validity are still in the early ...
A systematic search was performed across three databases (MEDLINE, PsycINFO and SCOPUS). The literature search was limited to the years from 2009 to 2021 and to the original English versions. Ten pape...
Four measures had at least one rating of 'good' across both dimensions of reliability and at least one dimension of validity and were deemed to have promising psychometric properties: the Clinical Out...
This review informs measurement choice for researchers and clinicians while highlighting a need for continued research efforts into the quality of measures available for people with IDs. The results w...
Educational opportunities occur through naturalistic everyday life experiences (e.g., reading a newspaper, listening to a podcast, or visiting a museum). Research primarily examines learning under con...
Working memory training (WMT) can offer therapeutic benefits to patients with neurodevelopmental disorders (NDD) and mild to borderline intellectual disability (MBID). However, consistent evidence for...
A double-blind randomised controlled trial in children (aged 10;0-13;11) with MBID (60 < IQ < 85) and ADHD and/or ASD evaluated the effects of a less intensive but prolonged version of the original Co...
We observed a significant effect of time on both primary and secondary outcome measures, indicating that all children improved in working memory performance and other neurocognitive and academic outco...
This study was unable to document superior effects of active personalised coaching and feedback compared with general non-personalised coaching and no feedback in an adaptive WMT in children with MBID...
The dynamic risk outcome scales (DROS) was developed to assess treatment progress of clients with mild intellectual disability or borderline intellectual functioning using dynamic risk factors. We stu...
Data of 250 forensic clients with intellectual disabilities were linked to recidivism data from the Judicial Information Service in the Netherlands. Receiver operating characteristics (ROC) analyses w...
The DROS total score could not significantly predict recidivism. A DROS recidivism subscale predicted general, violent and other recidivism. These predictive values were comparable to those of a Dutch...
The DROS recidivism subscale predicted various classifications of recidivism better than chance. At present, the DROS appears to have no added value beyond the HKT-30 for the purpose of risk assessmen...
Both learning disorders and bullying are major sources of public concern. Children with learning disorders often suffer from social rejection, potentially rendering them more susceptible to bullying i...
The current study used path analyses on a representative sample of 2,925 German 3rd and 4th grades to examine whether learning disorders are a direct bullying risk factor, or whether their impact depe...
Results indicated that learning disorders are not a direct but rather an indirect childhood risk factor for bully-victim involvement, depending on psychiatric comorbidity with internalizing or externa...
Children with learning disorders are at a higher risk of having psychiatric comorbidity, which in turn renders them at a higher risk of bullying involvement. Implications for bullying interventions an...